Literature DB >> 23678150

Why does acetylcholine exacerbate myasthenia caused by anti-MuSK antibodies?

Andrew G Engel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23678150      PMCID： PMC3678029          DOI： 10.1113/jphysiol.2013.254599

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  7 in total

1.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Authors:  Y Kawakami; M Ito; M Hirayama; K Sahashi; B Ohkawara; A Masuda; H Nishida; N Mabuchi; A G Engel; K Ohno
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

Review 2.  To build a synapse: signaling pathways in neuromuscular junction assembly.

Authors:  Haitao Wu; Wen C Xiong; Lin Mei
Journal:  Development       Date:  2010-04       Impact factor: 6.868

3.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice.

Authors:  Anna Rostedt Punga; Shuo Lin; Filippo Oliveri; Sarina Meinen; Markus A Rüegg
Journal:  Exp Neurol       Date:  2011-04-30       Impact factor: 5.330

5.  Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter.

Authors:  Thomas Misgeld; Terrance T Kummer; Jeff W Lichtman; Joshua R Sanes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

6.  Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals.

Authors:  Haipeng Zhu; Bula J Bhattacharyya; Hong Lin; Christopher M Gomez
Journal:  J Neurosci       Date:  2011-10-26       Impact factor: 6.167

7.  Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.

Authors:  Marco Morsch; Stephen W Reddel; Nazanin Ghazanfari; Klaus V Toyka; William D Phillips
Journal:  J Physiol       Date:  2013-02-25       Impact factor: 5.182
  7 in total
  2 in total

Review 1.  Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Authors:  Deepak Menon; Vera Bril
Journal:  Drugs       Date:  2022-05-31       Impact factor: 11.431

2.  Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis.

Authors:  Vishwendra Patel; Anne Oh; Antanina Voit; Lester G Sultatos; Gopal J Babu; Brenda A Wilson; Mengfei Ho; Joseph J McArdle
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.